Myriad Genetics' Colaris
This article was originally published in The Gray Sheet
Executive SummaryHereditary colon and endometrial cancer predictive medicine test is slated for launch in September, the firm announces. The test is used to assess an individual's risk of cancer based on the presence of a mutation in either of two genes, the firm explains. Myriad will begin accepting samples for testing nationwide next month. The test will be sold in the U.S. by the firm's existing 40-person oncology product sales force. Worldwide product rollout of the molecular diagnostic test will follow U.S. introduction
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.